Drugs / Fibrin Pad
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01166243 | Jul 2010 → Aug 2011 | hemorrhagic disease | Ethicon, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00977925 | Aug 2009 → Jan 2011 | hemorrhagic disease | Ethicon, Inc. | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fibrin Pad | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00977925 ↗ |
| Known as | Evarrest | “OBJECTIVES: To evaluate clinician-reported ease of use for the Evarrest fibrin sealant patch across various surgical bleeding situations.” PMID 26636489 ↗ Dec 2015 |
| Modality | Other / unclassified | “a novel combination hemostat (device/human biologic)” PMID 26041587 ↗ Nov 2015 |
| Route | Topical | “topical hemostats” PMID 26636489 ↗ Dec 2015 |